Aim: Ocular melanoma prefers to metastasize to the liver and the liver is the sole site of metastatic disease in 80% of patients. Until now there has been no standard treatment available and these patients have a very poor prognosis (median survival 2-5 months). Isolated hepatic perfusion may be an option in patients with irresectable hepatic ocular melanoma metastases. The aim of this study was to evaluate applicability, toxicity and response in this selected group of ocular melanoma patients by treatment with isolated hypoxic hepatic perfusion with retrograde outflow (IHHP) with melphalan. Methods: From September 2002 until July 2006 eight consecutive patients were included in this study. IHHP was performed with inflow via the hepatic artery and retrograde outflow via the portal vein during 25 min with 1 mg/kg melphalan. The perfusion was followed by a complete wash-out procedure. Results: The median total operation time was 4 h with a median blood/fluid loss of 1100 ml. No postoperative mortality was observed. Median hospital stay was 9.5 days. Toxicity was moderate: WHO grade 3 leukocytopenia in 3 patients, grade 3 hepatic toxicity in 1 patient. In 37% of patients (3/8) a partial response could be demonstrated 3 months after IHHP. Stable disease was found in 3 patients and progressive disease in 2 patients. Median time to local progression was 6 months and the median survival was 11 months. Conclusion: Melphalan-based IHHP with retrograde outflow is a safe treatment option for patients with irresectable ocular melanoma metastases. Survival benefit seems to be comparable to classical IHHP.

Additional Metadata
Keywords Hepatic metastasis, Isolated perfusion, Melanoma, Melphalan, adult, aged, article, bile duct disease, bile duct necrosis, bleeding, blood clotting disorder, cancer chemotherapy, cancer patient, cancer survival, cancer therapy, cholecystitis, clinical article, continuous infusion, dehydration, eye cancer, female, fever, gastrointestinal toxicity, hepatic artery, hospitalization, human, isolated hypoxic hepatic perfusion, leukopenia, liver metastasis, liver toxicity, male, melanoma, nephrotoxicity, portal vein, priority journal, surgical mortality, survival time, treatment response, wound infection
Persistent URL,
Journal European Journal of Surgical Oncology
van Etten, B, de Wilt, J.H.W, Brunstein, F, Eggermont, A.M.M, & Verhoef, C. (2009). Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. European Journal of Surgical Oncology, 35(5), 539–545. doi:10.1016/j.ejso.2008.07.004